Back

ICD prescription as primary prevention in dilated cardiomyopathy over 70 years old after the DANISH trial: single center experience

12 May 2024 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 2 Implantable Cardioverter-Defibrillator (ICD) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Javier Meseguer Donlo

Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)

7 More presentations in this session

Presentation thumbnail
Exercise capacity and factors associated in patients with heart failure
Doctor L. Klompstra (Linkoping, SE)
Abstract Slides Video
Presentation thumbnail
Beyond 3 Months: unraveling the prolonged Impact of optimized medical therapy on LVEF and ICD implantation in HFrEF Patients
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Heart failure etiology and ARNI + SGLT2i initiation may influence implantable cardioverter-defibrillator implantation timing
Doctor J. Quintal (Setubal, PT)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of implantable cardioverter defibrillators in heart failure: a comparative analysis between ischemic and non-ischemic cardiomyopathy patients
Doctor I. Ferreira Neves (Lisboa, PT)
Abstract Slides Video
Presentation thumbnail
ICD prescription as primary prevention in DCM in NYHA class I: single center experience
Miss M. Santalo i Corcoy (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 2

The Event

Event poster

Heart Failure 2024

12 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Primary prevention implantable cardioverter defibrillators are no longer indicated in non-ischaemic HFrEF: pro
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator
thumbnail
Congress Presentation
Limitations of current ICD indications in ischemic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources